Population-based serology reveals risk factors for RSV infection in children younger than 5 years.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
26 04 2021
Historique:
received: 06 01 2021
accepted: 08 04 2021
entrez: 27 4 2021
pubmed: 28 4 2021
medline: 11 11 2021
Statut: epublish

Résumé

Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization in infants. Underlying risk factors for RSV infection in the general population are not well understood, as previous work has focused on severe outcomes of infection in a clinical setting. Here we use RSV-specific IgG and IgA antibody measurements from two population-based cross-sectional serosurveys carried out in the Netherlands (n = 682) to classify children up to 5 years as seronegative or seropositive. We employ a generalized additive model to estimate the probability of prior RSV infection as function of age, date of birth within the year, and other risk factors. The analyses show that the majority of children have experienced a RSV infection before the age of 2 years. Age and birthdate are strong predictors of RSV infection in the first years of life, and children born in summer have higher estimated probability of infection than those born in winter [e.g., 0.56 (95% CI 0.45-0.66) vs. 0.32 (0.21-0.45) at age 1 year]. Our analyses reveal that the mean age at infection depends on date of birth, which has implications for the design of vaccination programmes and prioritisation schemes for the prophylactic use of monoclonal antibodies.

Identifiants

pubmed: 33903695
doi: 10.1038/s41598-021-88524-w
pii: 10.1038/s41598-021-88524-w
pmc: PMC8076290
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin A 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8953

Références

J Infect Dis. 2020 Sep 23;:
pubmed: 32964923
J Infect Dis. 2018 Jan 4;217(2):238-244
pubmed: 29112722
Epidemiol Infect. 2015 Mar;143(4):804-12
pubmed: 24901443
Am J Epidemiol. 2012 Nov 1;176(9):794-802
pubmed: 23059788
PLoS One. 2017 May 22;12(5):e0177803
pubmed: 28531224
Vaccine. 2003 Jul 28;21(24):3365-9
pubmed: 12850341
J Infect Dis. 2021 Feb 12;:
pubmed: 33576788
J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583
pubmed: 30880339
J Infect Dis. 2020 Oct 7;222(Suppl 7):S688-S694
pubmed: 32821916
J Infect Dis. 2020 Oct 7;222(Suppl 7):S599-S605
pubmed: 32815542
BMC Infect Dis. 2019 May 28;19(1):470
pubmed: 31138148
Acta Paediatr. 2003 Nov;92(11):1314-21
pubmed: 14696852
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Epidemiol Infect. 2016 Jun;144(8):1622-33
pubmed: 26732801
mSphere. 2019 Apr 24;4(2):
pubmed: 31019002
Lancet Glob Health. 2017 Oct;5(10):e984-e991
pubmed: 28911764
BMJ Open. 2016 Jun 02;6(6):e009337
pubmed: 27256085
mSphere. 2019 Sep 11;4(5):
pubmed: 31511367
Pediatr Infect Dis J. 2004 Sep;23(9):806-14
pubmed: 15361717
Infect Dis Ther. 2016 Sep;5(3):271-98
pubmed: 27480325

Auteurs

Stijn P Andeweg (SP)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 BA, Bilthoven, The Netherlands. stijn.andeweg@rivm.nl.

Rutger M Schepp (RM)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 BA, Bilthoven, The Netherlands.

Jan van de Kassteele (J)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 BA, Bilthoven, The Netherlands.

Liesbeth Mollema (L)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 BA, Bilthoven, The Netherlands.

Guy A M Berbers (GAM)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 BA, Bilthoven, The Netherlands.

Michiel van Boven (M)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 BA, Bilthoven, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH